G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients. Patients all accepted platinum-based chemotherapy 3-4 weeks once per course. The primary end is the incidence of FN in every course of chemotherapy. After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lei Li
• Treatments: Lenograstim

Criteria

Inclusion Criteria:

• Confirmed primary gynecologic cancer

• Good performance status

• Aged 18 years or older

• Signed an approved informed consents

• No immunosuppressive disease

Exclusion Criteria:

• Not meeting all of the inclusion criteria